2019 New Year's first single! Deqi pharmaceutical completed the financing of 120 million US dollars in round B, and made efforts to lay out the platform for original research and innovation of tumor drugs

On January 2, Deqi pharmaceutical announced the completion of a $120 million round B financing This round of financing is jointly led by fountain vest and Boyu capital, with celgene Corporation, Wuxi apptec venture capital fund and Taikang participating in the investment The existing investors Qiming venture capital and Taifu capital continue to follow the investment Deqi pharmaceutical is committed to the development and commercialization of the world's first new drugs, focusing on the differences and uniqueness of clinical product pipeline and clinical research and development At the beginning of its establishment, Deqi pharmaceutical was invested by American new base company and reached strategic cooperation In August 2017, Deqi pharmaceutical obtained a round of investment of 21 million US dollars led by Qiming venture capital For the unmet clinical needs of China and the Asia Pacific region, Deqi pharmaceutical focuses on the development and joint treatment of innovative tumor drugs The existing product pipeline covers three major treatment fields: solid tumor, blood tumor and virus infection Among them, atg-010 (selinexor) is the world's first new mechanism of nuclear protein export inhibitor (sine), which is comprehensively promoting clinical trials of various indications , its first indication - for relapsed refractory multiple myeloma products have entered the new drug market application stage (NDA) at home and abroad In addition, atg-008 is the world's first dual target drug targeting at hepatitis B positive liver cancer It is conducting international multi center clinical trials in mainland China, Taiwan and South Korea, and has obtained major national science and technology special support for "major new drug creation" during the 13th Five Year Plan period in China Under the background of drastic changes in the current capital market and great changes in the pharmaceutical industry, Deqi pharmaceutical, as the first innovative pharmaceutical enterprise to announce the completion of 120 million USD round B financing in 2019, is of milestone significance This round of financing funds will be mainly used to promote the continuous R & D and commercialization of atg-008, atg-010 and other products, expand the research and commercialization team, further expand the product pipeline through the combination of independent R & D and external cooperation, and create a comprehensive development platform for the development of new drugs for the original research of tumors Deqi pharmaceutical has completed the preparation workshop with a total area of 15792 square meters in Shaoxing, China, and is currently undergoing GMP decoration Its future production capacity can meet the production demand of the above products At the same time, Deqi pharmaceutical is establishing a commercial team to build a professional marketing system for the above products Dr Mei Jianming, founder and chairman of deqi pharmaceutical, said: "we are honored to be supported by top investment institutions at home and abroad, which is the recognition of deqi's business model, executive team, product pipeline and development strategy by the capital market The successful completion of this round of financing makes Deqi's development even more powerful We will continue to maintain a rigorous, scientific and patient-centered research and development spirit, give full play to our comparative advantages in clinical research and development, and actively prepare for commercialization, so that patients in China and the Asia Pacific region can use the clinically necessary drugs for life-threatening diseases as soon as possible " Li Zhen, managing director of Fangyuan capital, said, "compared with the global market, the proportion of innovative drugs in the Chinese pharmaceutical market is too low to meet the needs of Chinese clinical patients The adjustment of drug structure will bring market opportunities in the next decade or even 20 years, and Fangyuan capital will continue and patiently layout the field of innovative drugs in the long term It's a great honor to be the leading investment organization of such an excellent company as Deqi pharmaceutical Dr Mei and his team's extraordinary execution and understanding of the development trend of the focused treatment field are amazing We hope to make use of Fang Yuan's resources and experience in the field of medical treatment, and work with Deqi to contribute to the cause of innovative drugs in China " Cao Yanling, general manager of Boyu capital, said, "as a long-term investor in China's biopharmaceutical industry, Boyu capital is very honored to be the leading investor in the b-round financing of deqi pharmaceutical There are still a large number of unmet clinical needs in the field of cancer treatment in China The introduction of first in class / best in class drugs is an important way to improve the level of new drug research and development in China Dr Mei and Deqi's team's rich clinical development experience and a number of high-quality pipelines introduced since their establishment have laid a dominant position in their domestic counterparts We hope to join hands with Deqi to introduce more new and good drugs into China for the benefit of Chinese patients " About Deqi Deqi pharmaceutical is an innovative pharmaceutical company focusing on new drug development, clinical research and marketing, focusing on solving the unmet medical needs in Asia, and striving to provide the most cutting-edge and leading innovative anti-tumor and antiviral drugs for patients in China and Asia Pacific region In April 2017, the global innovative medicine leading enterprise Xinji company became a long-term strategic partner of deqi pharmaceutical and invested in Deqi At present, Deqi pharmaceutical has five products in clinical research and development stage: atg-010 is a product in research and development stage in which multiple myeloma, diffuse large B-cell lymphoma and multiple solid tumors are in NDA application and clinical phase II / III respectively; atg-008 has carried out clinical research on multi center liver cancer in Asia Pacific in many regions including Mainland China, Taiwan and South Korea; atg-016 and atg-019 Atg-527 is an antiviral drug in clinical research, which is in the first / second stage of clinical research and focuses on new targets and mechanisms of cancer treatment It is in the process of clinical research on the treatment of multiple types of cancer, including myelodysplastic syndrome, colorectal cancer and prostate cancer Atg-527 is an antiviral drug in clinical research and is currently in the process of treatment of influenza, respiratory syncytial virus and human beings The clinical study of herpes like virus infection and other related diseases has been completed About Fangyuan capital, founded in 2007, Fangyuan capital is one of the most mature independent private equity investment companies in Asia Fangyuan capital focuses on long-term investment in leading enterprises in the industry, and works closely with the management team to promote enterprise growth and create multiple values, including strategy, operation, finance and industry integration Fangyuan capital has completed a series of successful landmark investments in Asia, Europe and the United States, focusing on consumer, media and technology, health care, industry and financial services Fangyuan capital is supported by some of the world's largest sovereign wealth funds and public pension plans, with assets under management of nearly $5 billion About Boyu capital Boyu capital is one of the largest private equity companies in China Boyu has offices in Beijing and Hong Kong to provide long-term capital and operational advice to the best managed and most innovative companies in the TMT, healthcare, consumer / retail and financial services industries About celgene, headquartered in summit, New Jersey, USA, is a global enterprise mainly engaged in biopharmaceutics, and is committed to exploring, developing and commercializing drug products for the treatment of cancer and other serious diseases such as immune inflammation As a leading open capability and technology platform company in the world, Wuxi apptec provides all-round integrated laboratory R & D and production services from drug discovery, development to marketization in the fields of global pharmaceutical and medical devices With the purpose of taking research as the first task and customer as the center, Wuxi apptec helps global customers shorten the R & D cycle of drugs and medical devices and reduce the R & D cost through a cost-effective and efficient service platform The platform of Wuxi apptec includes the R & D and production of chemical drugs, the R & D and production of cell and gene therapy, the R & D of drugs, and the testing of medical devices It is carrying thousands of R & D and innovation projects from more than 3000 innovation partners in more than 30 countries around the world It is committed to bringing the latest and best medicine and health products to patients around the world, and realizing that "there is no hard medicine in the world, hard to treat Sick dream Taikang Taikang, founded in 1996, is one of the leading insurance and financial services groups in China Its business covers insurance, asset management and medical care By the end of 2017, Taikang's assets under management had exceeded 1.2 trillion yuan Medical and health care is the key investment field of Taikang In recent years, it has invested in many projects including Wuxi Wuxi Wuxi pharmaceutical, Mindray medical and Xinda biology Qiming venture capital was founded in 2006 and enjoys a high reputation in China's venture capital industry for its outstanding investment performance It has offices in Shanghai, Beijing, Suzhou, Hong Kong and Seattle In 2016, Qiming raised a fund to invest in health care in the United States and established Qiming America in Seattle At present, Qiming venture capital manages five US dollar funds and four RMB funds, with total assets under management of US $2.7 billion About Taifu capital, founded in 2014, Taifu capital focuses on new drug development and new medical technology research, mainly investing in potential early and growing enterprises The investment team has many years of experience and industry resources in these fields, and is committed to helping the invested enterprises grow into leading enterprises in the industry (source: medicine cube)